Day: April 26, 2021

Geneva, Switzerland, April 26, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has increased its share capital from 39,748,635 to 49,272,952 through the issue of 9,524,317 new registered shares at a nominal value of CHF1 each to Addex Pharma S.A, its 100% wholly-owned subsidiary. The new shares, issued from the Company’s authorized capital, are listed on the SIX Swiss Exchange. The transaction has been executed to provide the Group with additional future financing flexibility. “This transaction provides us with financing flexibility as we advance two programs into clinical trials, including our lead program dipraglurant for Parkinson’s disease levodopa-induced dyskinesia, and four programs...

Geneva, Switzerland, April 26, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, will present at the 4ᵗʰ Annual Neuroscience Innovation Forum (April 26 – 30, 2021). In his presentation, Mr Dyer will provide a corporate update and discuss recent developments at Addex. The video presentation will be available for viewing to registered participants at the forum. Mr Dyer will also be speaking at the Parkinson’s & Movement Disorders Panel scheduled for 13:20 EDT, April 28, 2021. Management will be available for virtual one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting with management, please contact...

April 26, 2021 First-quarter highlightsFollowing the agreement to sell the Domestic Appliances business to global investment firm Hillhouse Capital, this business is reported as a discontinued operation as of Q1 2021. Consequently, sales and results from the Domestic Appliances business are no longer included in the results of continuing operations. Group sales amounted to EUR 3.8 billion, with 9% comparable sales growth Comparable order intake decreased 5%, with double-digit growth in the Diagnosis & Treatment businesses and a double-digit decline in the Connected Care businesses on the back of 80% growth in Q1 2020 Income from continuing operations was a loss of EUR 34 million. Excluding the impact of a provision related to precautionary actions to address a component quality issue, income from continuing operations improved...

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 26 April 2021 Disclosure of received notification of The Capital Group Companies Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification of The Capital Group Companies, Inc. Notification of The Capital Group Companies, Inc. (“CGC”)On 22 April 2021 Fagron received a notification that the shareholdings of CGC had fallen below the disclosure threshold of 10% on 20 April 2021 as the result of the disposal of voting securities or voting rights. The notification is made by a ‘parent undertaking or a controlling person’. On 20 April 2021, CGC held a total of 7,027,476 voting rights.20 April 2021    CGC 0 0%Capital Research and Management Company 5,138,305 7.09%Capital Bank &...

Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 26 april 2021 Openbaarmaking van ontvangen kennisgeving van The Capital Group Companies Overeenkomstig de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen, heeft Fagron een kennisgeving ontvangen van The Capital Group Companies, Inc. Kennisgeving van The Capital Group Companies, Inc. (“CGC”)Op 22 april 2021 heeft Fagron een kennisgeving ontvangen dat het aandeelhouderschap van CGC op 20 april 2021 onder de kennisgevingsdrempel van 10% terecht is gekomen door de overdracht van stemrechtverlenende effecten of stemrechten. De kennisgeving vindt plaats door een ‘moederonderneming of een controlerende persoon’. Op 20 april 2021 bezit CGC in totaal 7.027.476 stemrechten.20 april 2021    CGC 0 0%Capital...

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 26 April 2021 Disclosure of received notification of Templeton Investment Counsel Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification of Templeton Investment Counsel, LLC. Notification of Templeton Investment Counsel, LLCOn 22 April 2021, Fagron received a notification that the shareholding of Templeton Investment Counsel, LLC had crossed the disclosure threshold of 3% on 20 April 2021 as the result of the acquisition of voting securities or voting rights. The notification is made by a ‘person that notifies alone’. On 20 April 2021, Templeton Investment Counsel, LLC held a total of 2,295,290 voting rights. Based on the denominator of 72,477,654 (total number of voting rights),...

Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 26 april 2021 Openbaarmaking van ontvangen kennisgeving van Templeton Investment Counsel Overeenkomstig de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen, heeft Fagron een kennisgeving ontvangen van Templeton Investment Counsel, LLC. Kennisgeving van Templeton Investment Counsel, LLCOp 22 april 2021 heeft Fagron een kennisgeving ontvangen dat het aandeelhouderschap van Templeton Investment Counsel, LLC op 20 april 2021 de kennisgevingsdrempel van 3% heeft overschreden door de verwerving van stemrechtverlenende effecten of stemrechten. De kennisgeving vindt plaats door een ‘persoon die alleen kennis geeft’. Op 20 april 2021 bezit Templeton Investment Counsel, LLC in totaal 2.295.290 stemrechten. Op basis...